Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the
 effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A
 coadministered with simvastatin) will be superior to atorvastatin on decreasing the low
 denisity lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio
 for the following dose comparisons: 2g/20 mg MK-0524B versus 10 mg atorvastatin, 2g/40 mg
 MK-0524B versus 20 mg atorvastatin, 2g/40 mg MK-0524B versus 40 mg atorvastatin, and 2g/40 mg
 MK-0524B versus 80 mg atorvastatin.
Inclusion Criteria:

 -  Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and
 190 mg/dL and Triglycerides between 150 and 500 mg/dL

 Exclusion Criteria:

 -  Pregnant or lactating women, or women intending to become pregnant

 -  Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or
 recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)

 -  Human immunodeficiency virus (HIV) positive

 -  Any of the following within the past 3 months: heart attack, stoke, heart bypass
 surgery, unstable angina, angioplasty

 -  Active or chronic liver disease